Printer Friendly

Boehringer Ingelheim obtains United States patent.

UAB Research Foundation (Birmingham, AL) has patented methods and reagents for the capture of primary HIV. A cell line expressing CCR5, CXCR4 and CD4 receptors binds and is infected by primary HIV. The cell line contains a marker gene sequence, the marker gene sequence expressed in near linear quantities over at least two orders of magnitude in response to HIV infection. Primary HIV is amplified to create a primary virus stock through insertion of an amplicon gene into the receptor expressing cell line. HIV amplification occurs rapidly and is operative with noninfectious HIV through amplification in the presence of an infectivity complement. The present invention is useful in determining host HIV titer, drug sensitivity, HIV amplification, gene sequencing and co-receptor utilization. (US 6,797,462)
COPYRIGHT 2004 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:UAB Research Foundation
Comment:[0] Boehringer Ingelheim obtains United States patent.(UAB Research Foundation)
Publication:BIOTECH Patent News
Article Type:Brief Article
Geographic Code:1USA
Date:Oct 1, 2004
Previous Article:Boehringer Ingelheim obtains United States patent.
Next Article:Boehringer Ingelheim obtains United States patent.

Related Articles
Valentis and Boehringer Ingelheim to collaborate on gene medicine for rheumatoid arthritis.
Lexicon Genetics extends gene targeting technology agreement.
MorphoSys widens scope of United States patent for HuCAL technology.
Jury renders decision in Schering-Plough animal vaccine infringement suit.
MorphoSys and Boehringer Ingelheim start new antibody program.
Boehringer Ingelheim obtains United States patent.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters